Cargando…
The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB(2) receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy
BACKGROUND: Chemotherapeutic agents produce dose-limiting peripheral neuropathy through mechanisms that remain poorly understood. We previously showed that AM1710, a cannabilactone CB(2) agonist, produces antinociception without producing central nervous system (CNS)-associated side effects. The pre...
Autores principales: | Deng, Liting, Guindon, Josée, Vemuri, V Kiran, Thakur, Ganesh A, White, Fletcher A, Makriyannis, Alexandros, Hohmann, Andrea G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502129/ https://www.ncbi.nlm.nih.gov/pubmed/22998838 http://dx.doi.org/10.1186/1744-8069-8-71 |
Ejemplares similares
-
Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery
por: Rahn, Elizabeth J, et al.
Publicado: (2014) -
Blockade of CB1 or Activation of CB2 Cannabinoid Receptors Is Differentially Efficacious in the Treatment of the Early Pathological Events in Streptozotocin-Induced Diabetic Rats
por: Spyridakos, Dimitris, et al.
Publicado: (2022) -
A peripheral CB(2) cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB(2) reporter mouse
por: Lin, Xiaoyan, et al.
Publicado: (2022) -
PM288. Preclinical Evaluation of Neutral Cannabinoid CB1 Receptor Antagonists and Cannabinoid CB1 Receptor Negative Allosteric Modulators for Treating Drug Addiction
por: Gardner, Eliot L., et al.
Publicado: (2016) -
Medicinal chemistry of cannabinoids
por: Vemuri, V Kiran, et al.
Publicado: (2015)